Cloverleaf Bio
Tracked across 1 events · 6 articles · First seen Sep 08, 2026 · Last active Sep 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Cloverleaf Bio, an RNA therapeutics company spun out of Yale University and headquartered in New Haven, Connecticut, closed an upsized and oversubscribed $33 million seed financing round. The round was led by 4BIO Capital and…
Impact: The central entity of the event, securing $33 million in oversubscribed seed financing to advance its engineered tRNA cancer therapeutics platform. The capital extends its runway and validates its preclinical data, though it remains a private, early-stage company.
Sep 08, 2026 · 6 articles
95
Cloverleaf Bio raised seed financingCloverleaf Bio $33M Seed Financing
85
4BIO Capital led financing round Cloverleaf BioCloverleaf Bio $33M Seed Financing
70
AbbVie invested in round Cloverleaf BioCloverleaf Bio $33M Seed Financing
70
Eli Lilly and Company invested in round Cloverleaf BioCloverleaf Bio $33M Seed Financing
70
Boehringer Ingelheim invested in round Cloverleaf BioCloverleaf Bio $33M Seed Financing
45
United States — National Cancer Institute funded research Cloverleaf BioCloverleaf Bio $33M Seed Financing
40
Draper Gain International invested in round Cloverleaf BioCloverleaf Bio $33M Seed Financing
40
Mission BioCapital invested in round Cloverleaf BioCloverleaf Bio $33M Seed Financing
40
American Cancer Society invested in round Cloverleaf BioCloverleaf Bio $33M Seed Financing
ERGEN INTELLIGENCE
Track Cloverleaf Bio live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard